Mike Voevodsky

Michael Voevodsky is CEO of MitoChem Therapeutics, Inc., a privately held pharmaceutical company developing new therapies for neurodegeneration and diseases associated with aging and mitochondrial dysfunction.  Prior MitoChem, Mike was CEO at RAMI Group, a privately held group of companies in the military, aerospace, transportation and advanced manufacturing markets focused on delivering highly reliable RF technologies and systems for mission critical applications. He co-founded Salutaris Medical Devices developing a breakthrough treatment for Wet Age-related Macular Degeneration, served as the vice president of marketing at Matrixx Initiatives, and was vice president of business development at Hextek Corporation (a UofA spinout), to name a few. He has a BS in Business with distinction from The University of Arizona, a graduate of the Eller Entrepreneurship Program,  and his MBA from Harvard Business School.